Enlivex (ENLV) Share-based Compensation (2013 - 2025)
Enlivex (ENLV) posted quarterly Share-based Compensation of $915000.0 for Q4 2025, little changed year-over-year from $917000.0 in Q4 2024, and up 226.79% quarter-over-quarter from $280000.0 in Q3 2025.
Enlivex (ENLV) Share-based Compensation (2013 - 2025) Analysis & Trends
Enlivex's Share-based Compensation history runs 13 years deep, the most recent figure standing at $915000.0 for Q4 2025.
- In Q4 2025, Share-based Compensation changed 0.22% year-over-year to $915000.0; the TTM figure through Dec 2025 stood at $1.8 million (down 13.66% YoY), while the FY2025 annual figure was $1.8 million, down 13.66% from the prior year.
- Share-based Compensation for Q4 2025 stood at $915000.0, up from $280000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $1.7 million in Q4 2021, with the low at $190000.0 in Q1 2021.
- The 5-year median for Share-based Compensation is $438500.0 (2022), against an average of $605350.0.
- The sharpest annual moves came in 2021 and 2022: Share-based Compensation jumped 1068.97% in 2021, then sank 55.34% in 2022.
- Enlivex's Share-based Compensation stood at $1.7 million in 2021, then plunged by 55.34% to $757000.0 in 2022, then sank by 47.16% to $400000.0 in 2023, then jumped by 129.25% to $917000.0 in 2024, then fell by 0.22% to $915000.0 in 2025.
- Business Quant data shows ENLV's Share-based Compensation at $915000.0 in Q4 2025, $280000.0 in Q3 2025, and $295000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Enlivex | 4.58 Mn | -1.17 Mn | - | 915,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 915,000.00 |
| Dec 31, 2025 | 915,000.00 |
| Sep 30, 2025 | 280,000.00 |
| Sep 30, 2025 | 280,000.00 |
| Jun 30, 2025 | 295,000.00 |
| Jun 30, 2025 | 295,000.00 |
| Mar 31, 2025 | 293,000.00 |
| Mar 31, 2025 | 293,000.00 |
| Dec 31, 2024 | 917,000.00 |
| Dec 31, 2024 | 917,000.00 |
| Sep 30, 2024 | 377,000.00 |
| Sep 30, 2024 | 377,000.00 |
| Jun 30, 2024 | 388,000.00 |
| Jun 30, 2024 | 388,000.00 |
| Mar 31, 2024 | 383,000.00 |
| Mar 31, 2024 | 383,000.00 |
| Dec 31, 2023 | 400,000.00 |
| Dec 31, 2023 | 400,000.00 |
| Sep 30, 2023 | 407,000.00 |
| Sep 30, 2023 | 407,000.00 |